No Data
No Data
This Cheap Biotech Offers Investors a Play on ALS If Trial Data Continues to Impress
By Ciara Linnane The fatal illness, also called Lou Gehrig disease, has few treatment options NeuroSense Therapeutics Ltd.'s stock rose 6.5% Tuesday, as analysts cheered data from the biotech's late
Express News | NeuroSense Shares Are Trading Higher After the Company Reported Results From a 12-month Analysis of Its PARADIGM Phase 2b Study Evaluating PrimeC in ALS Patients, Showing That Disease Progression Was Slowed by 36% Compared to the Placebo
NeuroSense Reports Results From 12-Month Analysis Of Its PARADIGM Phase 2b Study Evaluating PrimeC In ALS Patients; Disease Progression Was Slowed By 36% V Placebo
NeuroSense Reports Results From 12-Month Analysis Of Its PARADIGM Phase 2b Study Evaluating PrimeC In ALS Patients; Disease Progression Was Slowed By 36% V Placebo
Express News | Neurosense Therapeutics Ltd -Consistent Data Across Multiple Endpoints Underscore Potential of Primec to Redefine ALS Treatment Paradigm
Express News | Neurosense Therapeutics: Disease Progression Slowed by 36% in Participants Who Received Primec for 12 Months Vs Those Who Initially Received Placebo
Express News | Neurosense Therapeutics Ltd -Neurosense Planning for Phase 3 Clinical Study in U.S. and Europe
No Data
8 SecondsOP : whoop there it is!